Rovi recorded profit net of 53 million euros in the first quarter of this year, a figure that multiplies by more than two (+123%) achieved in the same period of 2021, as reported by the pharmaceutical company to the National Securities Markets Commission on Wednesday (CNMV).
gross result of Exploitation Rovi’s (Ebitda) rose 113% to €74.3 million in the first three months of the year, while its operating income rose 57% to €205.6 million, driven by third-party manufacturing, a 167% increase. in sales, and the pharmaceutical specialty business, which grew sales by 16%.
modern and rovik
For this year, Rovi hopes to revenue Operations increase between 15% and 20%.
Moderna and Rovi have announced a long-term collaboration to enhance the formulation, aseptic filling, inspection, labeling and packaging capabilities at Rovi’s facilities. rovik In Madrid, San Sebastian de los Reyes and Alcalá de Henares.
This new agreement, whose duration is ten years, consists of a series of Investment This is expected to increase manufacturing capacity at Rovi’s facilities in Madrid.
“Ever since the first vaccine against COVID-19 was launched in December 2020, Rovi, as the manufacturer of Moderna’s vaccine, has been a fundamental pillar in providing rapid response, flexible And Kovid is effective in bringing the vaccine to every corner of the world. Thanks to vaccines, we hope to see an end to the pandemic and a progressive return to normality”, highlighted Rovi President and CEO Juan López-Belmonte Encina.
Thanks to vaccines, we hope to see an end to the pandemic and a progressive return to normalcy
“The results for the first quarter of 2022 demonstrate our company’s ability to adapt, compete and consistently exceed the agreement signed with Moderna, and redirect the strategy of manufacturing activities to third-party products. high value addedSupported by the high level of technical expertise of our plants in different regions, allowed our third party manufacturing business to grow by 167% in the first quarter of 2022”, he added.
Similarly, the European Commission has authorized the marketing of OKD (risperidone ISM) for the treatment of schizophrenia in adults, including: endurance and effectiveness with oral risperidone. The product was launched in Germany in April.
Arrival in the United States
Rovi’s CEO has underlined that this launch has come to strengthen the company strategy Internationalization of the firm as one of its pillars of future growth.
Also, as mentioned, the company is currently going through a regulatory process in which States of America United to obtain marketing authorization for this product.
Ultimately, Rovi’s board of directors agreed to appoint, following a favorable report from the Appointments and Remuneration Committee. Marina del Coral Telezo As a new externally owned director by co-option system to cover the vacancy that occurred in July 2021 as a result of the death of the previous president and director Juan López-Belmonte López.
Rovi multiplies its quarterly profit by more than two after settlement with Moderna